TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04686305: A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Ad

Sponsor: AstraZeneca · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 304 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT04686305 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04686305 Rescue Dossier →